Intra-tumor Heterogeneity in Colorectal Cancer Progression and Treatment Response

结直肠癌进展和治疗反应的肿瘤内异质性

• 批准号: 9923472
• 负责人: Karin Marie Hardiman
• 金额: $ 17.5万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-08-01 至 2021-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9923472
• 关键词: Address; Aftercare; Algorithmic Analysis; Behavior; Bioinformatics; Biological; Biopsy; Biopsy Specimen; Cancer Biology; Cancer Etiology; Cancer Patient; Cessation of life; Clinical; Colorectal Cancer; Copy Number Polymorphism; Data; Defect; Development; Disease; Disease Progression; Distant Metastasis; Epigenetic Process; Frequencies; Future; Genes; Genetic; Genetic Heterogeneity; Geographic Locations; Geography; Glioblastoma; Goals; Heterogeneity; Individual; Knowledge; Lesion; Location; Malignant Lymph Node Neoplasm; Malignant Neoplasms; Malignant neoplasm of lung; Manuscripts; Mentorship; Metastatic Neoplasm to Lymph Nodes; Minority; Molecular; Mutation; Nature; Neoplasm Metastasis; Oncogenes; Operative Surgical Procedures; Pathway interactions; Patients; Phenotype; Population; Primary Lesion; Primary Neoplasm; Radiation; Radiation therapy; Rectal Cancer; Renal Cell Carcinoma; Research Personnel; Resected; Resistance; Role; Sampling; Shapes; Somatic Mutation; Techniques; Testing; Tissues; Tumor Suppressor Proteins; United States; Xenograft Model; Xenograft procedure; bioinformatics tool; cancer genetics; cancer therapy; chemotherapy; clinical phenotype; colon cancer patients; colorectal cancer metastasis; colorectal cancer progression; education planning; gain of function mutation; improved; individual patient; innovation; loss of function; lymph nodes; malignant breast neoplasm; multidisciplinary; novel; novel therapeutic intervention; prognostic value; recruit; rectal; response; subclonal heterogeneity; targeted treatment; therapy resistant; tissue resource; translational study; treatment response; tumor; tumor heterogeneity; tumor progression

PROJECT SUMMARY: Colorectal cancer (CRC) remains the 3rd most common cause of cancer-related death in the United States. Treatment depends on location and stage and often includes radiation, chemotherapy and surgery. CRC phenotype and response to therapy vary significantly. CRCs arise in part due to the accumulation of somatic mutations and Copy Number Variants (CNV's). No particular change has been found that fully predicts phenotype. We and others have identified genetic sub-clones in CRC. In other tumor types, recent studies have highlighted the potential role of genetic heterogeneity in tumor phenotype, but in CRC the role of heterogeneity and tumor sub-clones in tumor progression and response to therapy remains unknown. Thus, we hypothesize the following: Substantial intra-tumoral genetic heterogeneity is common in primary CRCs, and the distinct sub-clones present in a primary lesion underpin CRC biological behavior and clinical phenotype. Distinct sub-clones in the primary lesion give rise to CRC lymph node (LN) and distant metastases. The sub- clones present in a CRC lesion vary in their response to chemotherapy and radiation therapy. Three specific aims are proposed to address the overarching hypotheses: Specific Aim 1: We will characterize the extent and nature of genetic sub-clones in CRCs by studying somatic genetic alterations in multiple, distinct geographic regions from each tumor used in aims 2 and 3. We will use bioinformatics tools to integrate mutations and CNV's to define genetic sub-clones within each tumor and compare sub-clones across tumors. Specific Aim 2: To compare sub-clones in primary CRC's to those in patient-matched LN metastases in 20 patients with the goal of defining the role of sub-clonal populations in metastatic progression. The questions we propose to answer are these: 1. Are the sub-clones that metastasize to the LNs from the majority or minority clones in the primary tumor? 2. Are individual LN metastasis made up of single or multiple sub-clones? 3. When there are multiple LN metastasis in an individual patient, are they derived from the same sub-clone from the primary tumor or multiple different sub-clones? Specific Aim 3A: To assess relationships between the sub-clones in the tumor and the response of rectal cancer patients to pre-operative chemotherapy and radiation, by analyzing 40 matched primary rectal cancers before and after treatment. We hypothesize that some rectal cancer sub- clones are sensitive and others resistant to chemo- and radiation therapy. Aim 3B: In parallel, we will create xenograft models of 20 of the rectal cancers and assess whether they mimic the response to standard chemotherapy and radiation seen in the matched patients. This proposal will utilize innovative sequencing and bioinformatics techniques along with patient samples and clinical information. Ultimately, greater understanding of the genetic mechanisms underlying CRC progression and response to treatment will allow novel, targeted therapies to be proposed and tested. This project, the multidisciplinary mentorship team, and educational plan will prepare the candidate to be a fully independent investigator in the field of colorectal cancer genetics.

项目摘要： 结直肠癌（CRC）仍然是美国与癌症相关死亡的第三个最常见原因。 治疗取决于位置和阶段，通常包括放疗，化学疗法和手术。 CRC 表型和对治疗的反应差异很大。 CRC的部分原因是躯体的积累 突变和拷贝数变体（CNV）。没有发现完全预测的特定更改 表型。我们和其他人已经确定了CRC中的遗传亚基。在其他肿瘤类型中，最近的研究 强调了遗传异质性在肿瘤表型中的潜在作用，但在CRC中的作用 肿瘤进展和对治疗反应的异质性和肿瘤亚cl剂仍然未知。因此， 我们假设以下情况：大量肿瘤内遗传异质性在原发性CRC中很常见，并且 原发性病变中存在的不同亚cl骨基础CRC生物学行为和临床表型。 原发性病变中的不同亚c-lones产生CRC淋巴结（LN）和远处转移。子 - CRC病变中存在的克隆在对化学疗法和放射疗法的反应中有所不同。三个具体 提出了目的来解决总体假设：具体目的1：我们将表征范围和 通过研究多个不同地理的体细胞遗传改变，CRC中遗传亚cl孔的性质 目标2和3中使用的每个肿瘤区域。我们将使用生物信息学工具来整合突变和 CNV定义每个肿瘤内的遗传亚cl孔并比较跨肿瘤的子cl孔。具体目标2： 将初级CRC中的亚clones与20例患者的患者匹配的LN转移中的子话进行比较 定义亚连锁群体在转移进展中的作用的目标。我们提出的问题 答案是以下答案：1。是从大多数或少数族裔克隆中转移到LN的子词 原发性肿瘤？ 2。单个LN转移是由单个或多个子clones组成的吗？ 3。有 单个患者中的多个LN转移，它们是从初级派生的 肿瘤还是多个不同的子帽子？特定目的3a：评估子词之间的关系 通过分析40 治疗前后匹配的原发性直肠癌。我们假设某些直肠癌亚基 克隆敏感，其他对化学和放射疗法有抵抗力。 AIM 3B：并行，我们将创建 20个直肠癌的异种移植模型，并评估它们是否模仿对标准的反应 在匹配的患者中看到的化学疗法和放射线。该建议将利用创新的测序和 生物信息学技术以及患者样品和临床信息。最终，更大的理解 CRC进展和对治疗反应的遗传机制中的遗传机制将允许新颖，有针对性 要提出和测试的疗法。这个项目，多学科指导团队和教育计划 将使候选人成为大肠癌遗传学领域中完全独立的研究者。

项目成果

Development and characteristics of a multidisciplinary colorectal cancer clinic.

• DOI: 10.1016/j.amjsurg.2020.08.030
• 发表时间: 2021-04
• 期刊: American journal of surgery
• 影响因子: 3
• 作者: Vu JV;Morris AM;Maguire LH;De Roo AC;Mukkamala A;Krauss JC;Regenbogen SE;Hendren S;Hardiman KM
• 通讯作者: Hardiman KM